Myacyne (Neomycin Sulfate)

Neomycin Sulfate binds to the bacterial 30S ribosomal subunit, blocking the initiation of protein synthesis. This inhibition prevents the bacteria from producing essential proteins, leading to bacterial cell death and a reduction of the infection at the site of application.

The dosage and frequency of Myacyne are determined by the prescribing healthcare professional based on the type and extent of the skin condition. Patients should follow the prescriber’s instructions and the product label for proper application.

Safety data for Neomycin Sulfate in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order Myacyne, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Myacyne’s active ingredient, Neomycin Sulfate, belongs to the aminoglycoside class and offers broad‑spectrum activity against many Gram‑positive and Gram‑negative bacteria. Compared with bacitracin or mupirocin, neomycin provides a different resistance profile and may be preferred when those agents are unsuitable or when a combination product is required.

Store Myacyne at room temperature, below 25 °C, in its original packaging. Keep it away from moisture and direct light. Ensure the container is tightly closed after each use to maintain product stability.

Myacyne is applied directly to the cleaned, dry skin area. A thin layer should be spread over the affected site, usually 1–3 times daily, or as directed by the prescriber. Hands should be washed before and after application to avoid contamination.

The most serious risks include allergic contact dermatitis, which can present as severe rash, swelling, or blistering, and rare systemic toxicity such as nephrotoxicity or ototoxicity if significant absorption occurs. Immediate medical attention is required if any of these symptoms develop.

Myacyne should not be used by individuals with a known hypersensitivity to Neomycin Sulfate, other aminoglycosides, or any component of the formulation. It is also contraindicated on large, broken skin surfaces or when used in conjunction with other neomycin‑containing products without medical supervision.